Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/3/2026

Laboratory Monitoring in Tumor Lysis Syndrome

Definition and Monitoring of Laboratory Parameters

  • In patients with tumor lysis syndrome, comprehensive laboratory monitoring should include uric acid, potassium, phosphorus, calcium, creatinine, BUN, and LDH, with monitoring frequency of every 6 hours for the first 24 hours and daily thereafter, as recommended by the European Hematology Association 1
  • Laboratory TLS is defined by abnormalities in uric acid, potassium, phosphorus, and calcium levels, with specific thresholds for each parameter, including an increase in uric acid by >25% from baseline or values ≥476 mmol/L (8 mg/dL) 2
  • The American Society of Clinical Oncology recommends monitoring uric acid, potassium, phosphorus, and calcium levels in patients at high risk of tumor lysis syndrome 2

Monitoring Protocol

  • For high-risk patients, monitor LDH, uric acid, sodium, potassium, creatinine, BUN, phosphorus, and calcium every 12 hours for the first three days, then every 24 hours subsequently, as recommended by the National Comprehensive Cancer Network 1
  • For patients with established TLS, monitor vital parameters, serum uric acid, serum electrolytes, and renal function every 6 hours for the first 24 hours and daily thereafter, as recommended by the European Society for Medical Oncology 1

Renal Function Assessment

  • Reliable measurement of renal excretion function is essential, and creatinine clearance or estimated glomerular filtration rate (eGFR) can be used as surrogates, with the MDRD formula or Cockroft-Gault equation providing acceptable estimates of eGFR 2
  • The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend using eGFR to assess renal function in patients with tumor lysis syndrome 2

Clinical Significance and Pitfalls

  • Clinical TLS is defined by laboratory TLS plus at least one of renal failure, cardiac arrhythmia, or seizure, and requires prompt intervention, as recommended by the American College of Cardiology 2
  • Calcium gluconate should not be used to correct mild hypocalcemia, and urine alkalinization is not recommended in patients receiving rasburicase therapy, as recommended by the European Hematology Association 1
  • The American Society of Clinical Oncology recommends avoiding concurrent administration of allopurinol and rasburicase, and not using rasburicase in patients with G6PD deficiency 3

Tumor Lysis Syndrome Monitoring

Patient Risk Assessment and Monitoring

  • For patients at intermediate risk of tumor lysis syndrome, monitoring should be done every 24 hours with hydration and allopurinol administration, according to the Journal of Clinical Oncology 4
  • Patients at low risk of tumor lysis syndrome require close monitoring but may not necessarily need pharmacological prophylaxis, as recommended by the Journal of Clinical Oncology 4
  • The American Society of Clinical Oncology suggests that renal function is critical because renal impairment amplifies all metabolic complications of tumor lysis syndrome 4
  • The distinction between laboratory and clinical tumor lysis syndrome is crucial, as clinical tumor lysis syndrome requires immediate and aggressive intervention, including monitoring and treatment, as stated by the Journal of Clinical Oncology 4

Monitoring Tumor Lysis Syndrome in Pediatric Acute Lymphoblastic Leukemia

Risk Stratification Before Monitoring

  • Children younger than 6 months (any white‑blood‑cell count) or younger than 3 months (any count) are considered high‑risk for TLS. 5
  • Pre‑existing renal impairment, dehydration, or obstructive uropathy place patients at high risk for TLS. 6

Laboratory Monitoring Protocol

Initial 24‑Hour Monitoring Window

  • For high‑risk patients, measure uric acid, phosphate, potassium, calcium, creatinine, blood urea nitrogen, and LDH every 4–6 hours after the first chemotherapy dose. 6, 7, 8
  • Uric acid: Aim for a level < 8 mg/dL; if rasburicase is given, repeat the measurement 4 hours after the dose and then every 6–8 hours. 6, 8
  • Potassium: Any elevated result should be confirmed with a second sample to rule out pseudohyperkalemia caused by hemolysis. 7, 8
  • Creatinine/BUN: A rising creatinine indicates clinical TLS and warrants immediate nephrology consultation. 6
  • LDH: Continue serial LDH measurements until the value normalizes, which signals resolution of TLS. 6, 8

Extended Monitoring (Beyond 24 Hours)

  • After the first day, repeat the laboratory panel every 12 hours for the next three days, then daily until all parameters have returned to baseline.
  • If TLS has not manifested within 48 hours after completion of chemotherapy, the probability of subsequent TLS is essentially zero. 6, 7

Clinical Monitoring Parameters

  • Cardiac monitoring: Provide continuous ECG for patients whose potassium exceeds 6 mmol/L to detect QRS widening. 7

Facility Requirements for High‑Risk Patients

  • Chemotherapy for high‑risk children should be administered only in centers that have immediate access to dialysis services and intensive‑care units. 6, 8
  • Notify nephrology services in advance for all high‑risk patients; despite rasburicase use, approximately 1.5 % of pediatric patients still require dialysis. 6

Common Monitoring Pitfalls to Avoid

  • Verification of hyperkalemia: Always obtain a repeat potassium sample before initiating aggressive treatment to exclude spurious elevation from hemolysis. 7, 8
  • Insufficient monitoring frequency: Limiting laboratory checks to every 12–24 hours in high‑risk patients can miss rapid metabolic shifts that occur within the first 6 hours. 6
  • Premature cessation of monitoring: Continue surveillance until LDH has normalized, not merely until electrolyte abnormalities have resolved. 6, 8

REFERENCES

← Return to Home